DECIPHERA PHARMACEUTICALS IN's ticker is DCPH and the CUSIP is 24344T101. A total of 59 filers reported holding DECIPHERA PHARMACEUTICALS IN in Q4 2017. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,225,015 | -34.5% | 79,289 | -30.5% | 0.00% | – |
| Q4 2022 | $1,870,542 | -15.3% | 114,127 | -4.3% | 0.00% | – |
| Q3 2022 | $2,208,000 | +157.0% | 119,316 | +82.7% | 0.00% | – |
| Q2 2022 | $859,000 | +41.3% | 65,292 | -0.6% | 0.00% | – |
| Q1 2022 | $608,000 | -72.4% | 65,661 | -70.9% | 0.00% | – |
| Q4 2021 | $2,204,000 | -67.7% | 225,601 | +12.3% | 0.00% | -100.0% |
| Q3 2021 | $6,826,000 | -7.4% | 200,886 | -0.2% | 0.00% | 0.0% |
| Q2 2021 | $7,371,000 | -18.8% | 201,363 | -0.6% | 0.00% | -50.0% |
| Q1 2021 | $9,079,000 | -23.4% | 202,478 | -2.5% | 0.00% | 0.0% |
| Q4 2020 | $11,850,000 | +110.8% | 207,624 | +89.5% | 0.00% | +100.0% |
| Q3 2020 | $5,622,000 | +1457.3% | 109,570 | +1789.1% | 0.00% | – |
| Q4 2019 | $361,000 | +12.8% | 5,800 | -38.5% | 0.00% | – |
| Q3 2019 | $320,000 | +19.9% | 9,431 | -32.8% | 0.00% | – |
| Q3 2017 | $267,000 | – | 14,044 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| New Leaf Venture Partners, L.L.C. | 4,104,140 | $93,041,000 | 43.52% |
| SV Health Investors, LLC | 1,716,303 | $38,909,000 | 20.55% |
| PURA VIDA INVESTMENTS, LLC | 68,154 | $1,545,000 | 0.65% |
| Redmile Group, LLC | 683,880 | $14,658,000 | 0.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 77,000 | $1,746,000 | 0.62% |
| SPHERA FUNDS MANAGEMENT LTD. | 224,154 | $5,008,000 | 0.59% |
| EMERALD ADVISERS, LLC | 482,626 | $10,941,000 | 0.42% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 416,342 | $9,438,000 | 0.38% |
| Orbimed Advisors | 1,176,070 | $26,662,000 | 0.34% |
| VIKING GLOBAL INVESTORS LP | 2,394,625 | $54,286,000 | 0.33% |